基础医学与临床 ›› 2009, Vol. 29 ›› Issue (1): 74-77.

• 研究论文 • 上一篇    下一篇

雌激素下调人乳腺癌细胞系MCF-7高迁移率蛋白的表达

顾汝军 刘冬良 马允 汪伟   

  1. 解放军第82医院149临床部外二科 第四军医大学人体解剖与组织胚胎学教研室
  • 收稿日期:2008-04-18 修回日期:2008-06-13 出版日期:2009-01-25 发布日期:2009-01-25
  • 通讯作者: 汪伟

Estrogen down-regulated the expression of high mobility group box 1 in human breast cancer cell line MCF-7

Ru-jun GU, Dong-liang LIU, Yun MA, Wei WANG   

  1. Department of Surgery,the 149 Clinical Division, 82 Hospital of the Chinese People's Liberation Army Department of Human Anatomy, Histology and Embryology, the Fourth Military Medical University
  • Received:2008-04-18 Revised:2008-06-13 Online:2009-01-25 Published:2009-01-25
  • Contact: Wei WANG

摘要: 目的 探讨雌激素与其拮抗剂他莫昔芬对人乳腺癌细胞系MCF-7高迁移率族蛋白(HMGB1)表达的影响。方法 在培养的MCF-7细胞中分别加入无水乙醇、不同浓度的17-beta-雌二醇(E2)和他莫昔芬培养4 d后。用实时荧光定量PCR和Western blot技术检测HMGB1 mRNA和蛋白水平。结果 17-beta-E2浓度在10-6和10-4 mol/L时,HMGB1 mRNA和蛋白的表达均显著低于对照组(P<0.05)。他莫昔芬浓度在10-6 和10-4 mol/L时,HMGB1 mRNA和蛋白的表达显著高于对照组(P<0.05)。结论 雌激素能够下调HMGB1的表达,而其拮抗剂他莫昔芬则相反。

关键词: 乳腺肿瘤, 高迁移率族蛋白, 实时荧光定量PCR, 他莫昔芬

Abstract: Objective To investigate the effects of estrogen and tamoxifen on the expression of high mobility group box 1 (HMGB1) in human breast cancer cell line MCF-7. Methods MCF-7 cells were incubated with 17-beta E2 and tamoxifen at different concentrations for 4 d, respectively, with absolute ethanol as negative control. Real time RT-PCR and Western blotting were used afterward to detect the expression of HMGB1 at mRNA and protein level after different treatment to the cell line, respectively. Results Compared with ethanol control, HMGB1 mRNA and protein levels were significantly decreased when 17-beta-E2 was added at concentrations of 10-6 and 10-4 mol/L (P<0.05). And HMGB1 expression was significantly increased when tamoxifen was added at concentrations of 10-6 and 10-4 mol/L (P<0.05). Conclusion Estrogen could down-regulate the expression of HMGB1, while its antagonist tamoxifen has an opposite effect. So, HMGB1 probably has an inhibitory effect on breast neoplasms proliferation.

Key words: Breast neoplasms, High mobility group box 1, Real-time RT-PCR, Tamoxifen